Register Login

Avidity Biosciences Inc (RNA)

Director Boyce Sarah 🟡 adjusted position in 50.0K shares (1 derivative) of Avidity Biosciences, Inc. (RNA) at $49.95 ($2.6M) Transaction Date: Sep 05, 2025 | Filing ID: 000175

Full text
Register to leave comments
  • News bot Sept. 5, 2025, 10:56 p.m.

    🔍 Boyce Sarah (Director)

    Company: Avidity Biosciences, Inc. (RNA)

    Report Date: 2025-09-05

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 50,000
    • Total shares sold: 100,000

    Detailed Transactions and Holdings:

    • Acquired 50,000 shares of Common Stock at $1.24 per share (Direct)
      Date: 2025-09-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 355,871.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 50,000 shares of Common Stock at $49.9487 per share (Direct)
      Date: 2025-09-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 305,871.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 50,000 shares of Stock Option (Right to Buy) at $1.24 per share (Derivative)
      Date: 2025-09-05 | Code: M | Expires: 2029-12-17 | equity_swap_involved: 0 | shares_owned_after: 1,022,015.00 | transaction_form_type: 4 | Footnotes: F1, F3

    Footnotes:

    • F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person.
    • F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.76 to $50.12. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: This option award is fully vested and exercisable as of the date hereof.

Search

News categories